Plus Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights

Posted: October 21, 2022 at 2:22 am

Awarded $17.6 million Product Development Research grant by the Cancer Prevention & Research Institute of Texas (CPRIT) to fund 186RNL development for leptomeningeal metastases (LM)

More here:
Plus Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights

Related Posts